



# ACIP Meningococcal Vaccines Work Group Introduction

Katherine Poehling, MD, MPH

June 23, 2022

# Meningococcal Vaccines Work Group

- ACIP Members
  - Katherine Poehling (Chair)
  - Lynn Bahta
  - Jamie Loehr
- Ex officio members
  - Margaret Bash (FDA)
  - Mark Connelly (FDA)
- CDC Lead
  - Sam Crowe (DBD/NCIRD)
- Liaisons and Consultants
  - Amra Resic (AAFP)
  - Samir Shah (AAP)
  - Sharon McMullen (ACHA)
  - Paul Cieslak (CSTE)
  - Jeff Goad (NFID)
  - Jessica Cataldi (PIDS)
  - Amy Middleman (SAHM)
  - David Stephens (Emory)
  - Denise De Las Nueces (BHCHP)
  - April Ramsey — (BHCHP)
- CDC Contributors
  - Alison Albert (DBD/NCIRD)
  - LeAnne Fox (DBD/NCIRD)
  - Rachel Gorwitz (DBD/NCIRD)
  - Susan Hariri (DBD/NCIRD)
  - Lucy McNamara (DBD/NCIRD)
  - Jonathan Duffy (DHQP/NCEZID)
  - Tanya Myers (DHQP/NCEZID)
  - Liz Velazquez (ISD/NCIRD)
  - Jessica MacNeil (ACIP Secretariat)
- GRADE/EtR support
  - Doug Campos-Outcalt (Arizona)
  - Rebecca Morgan (McMaster)

# Meningococcal Work Group Terms of Reference: Purpose and Initial Projects

- Review current data including effectiveness, immunogenicity, epidemiology, and cost-effectiveness of meningococcal vaccines
- Review current recommendations considering up-to-date evidence
- Propose updates to recommendations for meningococcal vaccine as needed
- Initial Projects
  - Incorporate Menveo Solution into current Menveo recommendations
  - Consider whether to expand the quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccine recommendations to include people experiencing homelessness
  - Develop proposed recommendations for two new pentavalent vaccines (MenABCWY) with anticipated licensure in late 2023 to early 2024

# Background on Menveo

- Menveo consists of two vials that are combined prior to administration
  - Lyophilized MenA component
  - Liquid MenCWY component
- Licensed for 2 months to 55 years
- Important product for vaccinating young children

# Menveo Solution

- New formulation: Menveo Solution will be all liquid and in one vial
- Components of Menveo Solution are same as with Menveo
- Precautions and contraindications remain the same
- Menveo Solution likely will be licensed for 10 years to 55 years
- GSK intends to maintain a small supply of lyophilized Menveo for children <2 years (note: MenQuadfi is available for children 2 to <10 years)

# Next Steps

- ACIP Secretariat and VFC determined do not need ACIP vote for Menveo Solution
- Plan for VFC
  - Publish an updated resolution based on new vaccine presentation
  - Work with GSK, public health departments, and providers to ensure Menveo remains available for children <2 years
- Work group tasks
  - GSK presentation on Menveo Solution next month
  - VFC presentation next month
  - WG to provide feedback to GSK and VFC
  - Share update at October ACIP meeting

# Thank You

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

